

Palforzia

- This form of peanut oral immunotherapy (OIT) was approved by the FDA in February 2020.
- It is indicated for patients 4 to 17 years old with a confirmed diagnosis of peanut allergy.
- The intent of this oral therapy is to decrease the risk of allergic reactions that may occur after accidental exposure to peanut.
- Palforzia is not a cure and does not completely eliminate the possibility of an allergic reaction with accidental peanut exposure.
- Palforzia is intended to be used along with a peanut avoidant diet. It needs to be taken by the patient indefinitely.
- While taking Palforzia a form of epinephrine still needs to be readily available.
- At this time we are deciding whether or not to offer this on an individual patient basis.
- If you have further questions, we encourage you to make an appointment to speak with one of the physicians.
- You can reach us by calling 708-246-4515.